查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1967609

组织与器官移植市场－全球产业规模、份额、趋势、机会与预测：按产品、应用、地区和竞争格局划分，2021-2031年

Tissue And Organ Transplantation Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product, By Application, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 185 Pages | 商品交期: 2-3个工作天内

价格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

简介目录

全球组织和器官移植市场预计将从 2025 年的 186.2 亿美元成长到 2031 年的 310.7 亿美元，复合年增长率为 8.91%。

此领域涵盖将供体生物组织或器官移植给受体，以恢復器官衰竭后生理功能的医疗干预措施。市场成长的主要驱动力是全球慢性病（包括心血管疾病和肾臟疾病）发生率的上升，这导致对替代疗法的需求显着增加。此外，医疗基础设施的加强和更有效的免疫抑制疗法的研发也促进了市场成长，这些因素共同提高了术后存活率和患者的长期健康状况。

市场概览
预测期 2027-2031
市场规模：2025年 186.2亿美元
市场规模：2031年 310.7亿美元
复合年增长率：2026-2031年 8.91%
成长最快的细分市场 纸巾製品
最大的市场 北美洲

儘管取得了这些进展，器官移植产业仍面临一个重大障碍：捐赠者器官严重短缺，而等待移植的人数却在不断增加。这种供需失衡造成了严重的瓶颈，严重限制了每年可进行的移植手术数量，儘管临床需求量很大。根据全球捐赠与移植观察站的数据，2024年全球整体进行了172,397例固态器官移植手术。这一数字凸显出，器官供应不足仍然是满足日益增长的国际移植手术需求的一大挑战。

市场驱动因素

外科手术技术和器官保存技术的创新是推动市场扩张的核心动力。尤其值得注意的是，捐赠器官在体外存活时间的延长。诸如常温机械灌注等先进技术能够使器官在运输过程中保持功能，最大限度地减少缺血性损伤，并使以前被认为无法使用的器官得以利用。从静态冷冻保存转向动态保存系统提高了器官利用率，并简化了复杂的物流操作。例如，Transmedics集团在其2024年10月发布的2024年第三季财报中报告称，由于其专有的肺、心臟和肝臟器官护理系统在临床上的应用范围扩大，收入净额显着增长至1.088亿美元。

慢性疾病，尤其是末期肾功能衰竭和肝功能衰竭衰竭的日益普遍，进一步加剧了对生物替代疗法的迫切需求。人口老化、生活方式改变以及高血压和糖尿病的增加等因素，加速了患者发展至末期器官衰竭的速度，使他们需要即时进行器官移植。供体器官供应与需要治疗的患者数量之间持续存在的缺口，给医疗系统带来了巨大的压力，迫使其改进器官获取工作。根据美国卫生资源与服务管理局 (HRSA) 2024 年 3 月发布的器官捐赠统计数据，超过 10.3 万名候选人登记在国家移植等待名单上，凸显了慢性器官衰竭患者的等待现状。此外，美国器官分配网络 (UNOS) 在 2024 年报告称，美国上年度完成了超过 4.6 万例器官移植手术，达到了一个里程碑，这表明美国致力于满足日益增长的临床需求。

市场挑战

供体器官严重短缺是限制组织和器官移植市场成长潜力的根本阻碍因素。这种短缺严格限制了手术数量，直接限制了医疗设备製造商和移植中心的商机。即使拥有先进的手术基础设施和高临床需求，由于无法获得足够的手术所需生物材料，市场也难以有效扩张。这种供需缺口导致手术数量增长停滞，造成相当一部分合格的患者无法获得所需的治疗。

近期来自主要移植网路的统计数据凸显了这一瓶颈的严重性，揭示了资源可用性与临床需求之间的巨大差距。根据2024年器官取得和移植网路（OPTN）的数据，美国国家移植等待名单上有超过10.3万名候选人。这一数字表明，移植手术的需求远远超过现有供给，从根本上阻碍了市场扩张以满足实际需求。因此，该行业面临永久性的运作上限，阻碍了这些救命手术本来可以带来的潜在收入的产生。

市场趋势

利用基因改造器官进行异种移植的出现，正在创造一种新的可移植组织来源，有望缓解捐赠者严重短缺的问题。生技公司正利用基因编辑技术改造猪器官，去除导致排斥反应的抗原，并引入确保生物相容性的人类调控因子。这项进展使器官移植摆脱了对人类捐赠者的依赖，并为那些在等待移植期间面临高死亡风险的患者提供了一种可扩展的替代方案。根据eGenesis公司于2025年2月发布的最新报告《eGenesis成功完成第二例基因编辑猪肾移植》，该公司已成功完成第二例使用基因编辑肾臟进行的人体移植手术，证明了这种非人类器官的临床可行性。

同时，微创手术和机器人辅助移植技术正不断发展，提高了手术精度，并加快了术后恢復。先进机器人平台的引入使外科医生能够比开放性手术更灵活地完成复杂的血管吻合术，从而缩短住院时间，并最大限度地减少併发症。这项技术进步不仅改善了临床疗效，也扩大了高风险患者的手术适应症范围，使那些以往仿单标示外传统手术的患者也能接受手术。根据直觉外科公司（Intuitive Surgical）于2025年1月发布的“2024年第四季及全年中期业绩报告”，2024年全球使用达文西手术系统进行的手术数量增长了约17%，这证实了这些平台正在迅速融入复杂的医疗程序中。

目录

第一章概述

第二章：调查方法

第三章执行摘要

第四章：客户心声

第五章：全球组织与器官移植市场展望

  • 市场规模及预测
    • 按金额
  • 市占率及预测
    • 副产品（组织製品、防腐剂、免疫抑制剂）
    • 透过应用（器官移植、组织移植）
    • 按地区
    • 按公司（2025 年）
  • 市场地图

第六章：北美组织与器官移植市场展望

  • 市场规模及预测
  • 市占率及预测
  • 北美洲：国别分析
    • 我们
    • 加拿大
    • 墨西哥

第七章：欧洲组织与器官移植市场展望

  • 市场规模及预测
  • 市占率及预测
  • 欧洲：国别分析
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙

第八章：亚太地区组织与器官移植市场展望

  • 市场规模及预测
  • 市占率及预测
  • 亚太地区：国别分析
    • 中国
    • 印度
    • 日本
    • 韩国
    • 澳洲

第九章：中东和非洲组织及器官移植市场展望

  • 市场规模及预测
  • 市占率及预测
  • 中东与非洲：国别分析
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 南非

第十章：南美洲组织与器官移植市场展望

  • 市场规模及预测
  • 市占率及预测
  • 南美洲：国别分析
    • 巴西
    • 哥伦比亚
    • 阿根廷

第十一章 市场动态

  • 促进因素
  • 任务

第十二章 市场趋势与发展

  • 併购
  • 产品发布
  • 近期趋势

第十三章 全球组织与器官移植市场：SWOT分析

第十四章：波特五力分析

  • 产业竞争
  • 新进入者的潜力
  • 供应商的议价能力
  • 顾客权力
  • 替代品的威胁

第十五章 竞争格局

  • Artivion, Inc
  • Folio Biosciences LLC
  • Arthrex, Inc.
  • Abbvie Inc.
  • Zimmer Biomet Holdings, Inc.
  • India Medtronic Private Limited
  • Novartis AG
  • Stryker Corporation
  • BiolifeSolutions Inc.
  • Teva Pharmaceutical Industries Ltd.

第十六章 策略建议

第十七章：关于研究公司及免责声明

简介目录
Product Code: 24301

The Global Tissue And Organ Transplantation Market is projected to expand from USD 18.62 Billion in 2025 to USD 31.07 Billion by 2031, reflecting a compound annual growth rate (CAGR) of 8.91%. This sector covers medical interventions where biological tissues or organs are transferred from a donor to a recipient to restore physiological function following organ failure. The market's upward trajectory is primarily driven by the rising global incidence of chronic ailments, including cardiovascular and renal diseases, which create a substantial need for replacement therapies. Furthermore, growth is reinforced by enhancements in medical infrastructure and the development of more effective immunosuppressive regimens, which collectively improve survival rates and long-term patient health post-surgery.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 18.62 Billion
Market Size 2031USD 31.07 Billion
CAGR 2026-20318.91%
Fastest Growing SegmentTissue Products
Largest MarketNorth America

Despite these advancements, the industry confronts a major obstacle in the form of a severe scarcity of donor organs compared to the expanding waiting lists. This imbalance creates a significant bottleneck that strictly limits the number of procedures that can be conducted each year, even amidst high clinical necessity. Data from the Global Observatory on Donation and Transplantation indicates that in 2024, a total of 172,397 solid organ transplants were performed worldwide. This figure emphasizes the persistent difficulty posed by supply limitations in satisfying the growing international demand for transplant surgeries.

Market Driver

Technological innovations in surgical methods and organ preservation act as a central catalyst for market expansion, notably by prolonging the viability of donor organs outside the human body. Advanced techniques, such as normothermic machine perfusion, enable organs to maintain functionality during transport, which minimizes ischemic damage and allows for the utilization of organs that were previously considered marginal. This transition from static cold storage to dynamic preservation systems increases utilization rates and facilitates complex logistical operations. For instance, TransMedics Group, Inc. reported in their 'Third Quarter 2024 Financial Results' from October 2024 that net revenue reached $108.8 million, a significant increase driven by the rising clinical adoption of their proprietary Organ Care System for lung, heart, and liver programs.

The rising prevalence of chronic conditions, specifically end-stage renal disease and liver failure, continues to heighten the urgent need for biological replacement therapies. Factors such as aging populations, lifestyle choices, and the increasing burden of hypertension and diabetes are quickening the pace at which patients develop terminal organ dysfunction, requiring immediate transplantation. This enduring disparity between the availability of donor grafts and the number of patients needing treatment places immense pressure on healthcare systems to improve procurement efforts. According to the Health Resources and Services Administration's 'Organ Donation Statistics' from March 2024, over 103,000 candidates were on the national transplant waiting list, illustrating the backlog of chronic organ failure patients. Additionally, the United Network for Organ Sharing noted in 2024 that the U.S. reached a milestone by conducting over 46,000 transplants in the prior year, signaling strong efforts to meet this escalating clinical demand.

Market Challenge

The severe insufficiency of available donor organs acts as a fundamental restriction on the growth potential of the tissue and organ transplantation market. This scarcity imposes a hard limit on the number of procedures that can be performed, which directly curtails the revenue opportunities for medical device manufacturers and transplant centers. Even with advanced surgical infrastructure and high clinical demand, the market struggles to scale efficiently because the necessary biological materials for surgeries are not available in adequate numbers. This gap between supply and demand causes a forced stagnation in procedural growth, leaving a substantial segment of the eligible patient population without necessary care.

The scale of this bottleneck is underscored by recent statistics from major transplant networks, which reveal the stark contrast between resource availability and clinical necessity. According to data from the Organ Procurement and Transplantation Network in 2024, there were over 103,000 candidates registered on the national transplant waiting list in the United States. This figure illustrates that the requirement for transplant interventions vastly outstrips the existing supply, mechanically preventing the market from expanding to satisfy the actual population needs. Consequently, the industry encounters a permanent cap on its operational capacity, hindering the generation of potential revenue that would otherwise result from these life-saving operations.

Market Trends

The emergence of xenotransplantation involving genetically engineered organs is creating a novel source of graftable tissues to mitigate the severe donor shortage. Biotechnology firms are deploying gene-editing technologies to alter porcine organs, removing antigens that trigger rejection and incorporating human regulators to guarantee biocompatibility. This progress steers transplantation away from sole reliance on human donors, presenting a scalable alternative for patients who otherwise face high mortality risks while waiting. As reported by eGenesis in February 2025 within their update 'eGenesis Announces Second Patient Successfully Transplanted with Genetically Engineered Porcine Kidney,' the company successfully performed its second human transplant using a gene-edited kidney, validating the clinical feasibility of this non-human source.

Concurrently, the transition toward minimally invasive and robotic-assisted transplant surgeries is refining procedural accuracy and enhancing post-operative recovery. The adoption of sophisticated robotic platforms enables surgeons to execute intricate vascular anastomoses with greater dexterity than open methods, thereby reducing hospital stays and minimizing complications. This technological advancement not only improves clinical results but also extends surgical eligibility to high-risk patients who were previously considered unsuitable for traditional procedures. According to the 'Intuitive Announces Preliminary Fourth Quarter and Full Year 2024 Results' report by Intuitive Surgical in January 2025, global procedures utilizing da Vinci surgical systems increased by roughly 17% in 2024, underscoring the rapid integration of these platforms into complex medical treatments.

Key Market Players

  • Artivion, Inc
  • Folio Biosciences LLC
  • Arthrex, Inc.
  • Abbvie Inc.
  • Zimmer Biomet Holdings, Inc.
  • India Medtronic Private Limited
  • Novartis AG
  • Stryker Corporation
  • BiolifeSolutions Inc.
  • Teva Pharmaceutical Industries Ltd.

Report Scope

In this report, the Global Tissue And Organ Transplantation Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Tissue And Organ Transplantation Market, By Product

  • Tissue Products
  • Preservation Solutions
  • Immunosuppressive Drugs

Tissue And Organ Transplantation Market, By Application

  • Organ Transplantation
  • Tissue Transplantation

Tissue And Organ Transplantation Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Tissue And Organ Transplantation Market.

Available Customizations:

Global Tissue And Organ Transplantation Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Tissue And Organ Transplantation Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Product (Tissue Products, Preservation Solutions, Immunosuppressive Drugs)
    • 5.2.2. By Application (Organ Transplantation, Tissue Transplantation)
    • 5.2.3. By Region
    • 5.2.4. By Company (2025)
  • 5.3. Market Map

6. North America Tissue And Organ Transplantation Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Product
    • 6.2.2. By Application
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Tissue And Organ Transplantation Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Product
        • 6.3.1.2.2. By Application
    • 6.3.2. Canada Tissue And Organ Transplantation Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Product
        • 6.3.2.2.2. By Application
    • 6.3.3. Mexico Tissue And Organ Transplantation Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Product
        • 6.3.3.2.2. By Application

7. Europe Tissue And Organ Transplantation Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Product
    • 7.2.2. By Application
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Tissue And Organ Transplantation Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Product
        • 7.3.1.2.2. By Application
    • 7.3.2. France Tissue And Organ Transplantation Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Product
        • 7.3.2.2.2. By Application
    • 7.3.3. United Kingdom Tissue And Organ Transplantation Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Product
        • 7.3.3.2.2. By Application
    • 7.3.4. Italy Tissue And Organ Transplantation Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Product
        • 7.3.4.2.2. By Application
    • 7.3.5. Spain Tissue And Organ Transplantation Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Product
        • 7.3.5.2.2. By Application

8. Asia Pacific Tissue And Organ Transplantation Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Product
    • 8.2.2. By Application
    • 8.2.3. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Tissue And Organ Transplantation Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Product
        • 8.3.1.2.2. By Application
    • 8.3.2. India Tissue And Organ Transplantation Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Product
        • 8.3.2.2.2. By Application
    • 8.3.3. Japan Tissue And Organ Transplantation Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Product
        • 8.3.3.2.2. By Application
    • 8.3.4. South Korea Tissue And Organ Transplantation Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Product
        • 8.3.4.2.2. By Application
    • 8.3.5. Australia Tissue And Organ Transplantation Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Product
        • 8.3.5.2.2. By Application

9. Middle East & Africa Tissue And Organ Transplantation Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Product
    • 9.2.2. By Application
    • 9.2.3. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Tissue And Organ Transplantation Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Product
        • 9.3.1.2.2. By Application
    • 9.3.2. UAE Tissue And Organ Transplantation Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Product
        • 9.3.2.2.2. By Application
    • 9.3.3. South Africa Tissue And Organ Transplantation Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Product
        • 9.3.3.2.2. By Application

10. South America Tissue And Organ Transplantation Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Product
    • 10.2.2. By Application
    • 10.2.3. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Tissue And Organ Transplantation Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Product
        • 10.3.1.2.2. By Application
    • 10.3.2. Colombia Tissue And Organ Transplantation Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Product
        • 10.3.2.2.2. By Application
    • 10.3.3. Argentina Tissue And Organ Transplantation Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Product
        • 10.3.3.2.2. By Application

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Tissue And Organ Transplantation Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Artivion, Inc
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Folio Biosciences LLC
  • 15.3. Arthrex, Inc.
  • 15.4. Abbvie Inc.
  • 15.5. Zimmer Biomet Holdings, Inc.
  • 15.6. India Medtronic Private Limited
  • 15.7. Novartis AG
  • 15.8. Stryker Corporation
  • 15.9. BiolifeSolutions Inc.
  • 15.10. Teva Pharmaceutical Industries Ltd.

16. Strategic Recommendations

17. About Us & Disclaimer